OKYO Pharma logo

OKYO - OKYO Pharma Share Price

18p 1.8  11.1%

Last Trade - 07/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £100.9m
Enterprise Value £100.8m
Revenue £n/a
Position in Universe 930th / 1819
Bullish
Bearish
Unlock OKYO Revenue
Momentum
Relative Strength (%)
1m +220.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.26%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 September 2019, OKYO Pharma Ltd revenues was not reported. Net loss decreased 27% to £871K. Lower net loss reflects Operating expenses decrease of 41% to £594K (expense), Other losses decrease from £18K (expense) to £0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OKYO Revenue Unlock OKYO Revenue

Net Income

OKYO Net Income Unlock OKYO Revenue

Normalised EPS

OKYO Normalised EPS Unlock OKYO Revenue

PE Ratio Range

OKYO PE Ratio Range Unlock OKYO Revenue

Dividend Yield Range

OKYO Dividend Yield Range Unlock OKYO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OKYO EPS Forecasts Unlock OKYO Revenue
Profile Summary

OKYO Pharma Limited is a United Kingdome-based biopharmaceutical company. The Company’s operating segment is research and development of biotechnological and pharmaceutical products. The Company focuses on G-protein coupled receptors (GPCR) based therapeutics for eye diseases and non-opioid analgesics for chronic pain. It is developing drug candidates for the treatment of dry-eye, uveitis, ocular and chronic pain. The Company’s therapeutic approach is to develop drug candidates that target inflammatory pathways using membrane-tethered ligand technology. The Company focuses to suppress the inflammation associated with the uveitis using its anti-inflammatory compound. Its product candidates include OKYO-0101 and OHYO-0201. The OKYO-0101 is focused on uveitis and allergic conjunctivitis. The OHYO-0201 is focused on ocular pain and chronic pain. OKYO Pharma US Inc is the subsidiary of the Company.

Directors
Last Annual March 31st, 2019
Last Interim September 30th, 2019
Incorporated July 3, 2018
Public Since July 17, 2018
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange London Stock Exchange (Full)
Shares in Issue 560,471,919
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OKYO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OKYO
Upcoming Events for OKYO
Frequently Asked Questions for OKYO Pharma
What is the OKYO Pharma share price?

As of 07/08/20, shares in OKYO Pharma are trading at 18p, giving the company a market capitalisation of £100.9m. This share price information is delayed by 15 minutes.

How has the OKYO Pharma share price performed this year?

Shares in OKYO Pharma are currently trading at 18p and the price has moved by 0.397k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the OKYO Pharma price has moved by 0.486k% over the past year.

What are the analyst and broker recommendations for OKYO Pharma?

Of the analysts with advisory recommendations for OKYO Pharma, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for OKYO Pharma is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will OKYO Pharma next release its financial results?

OKYO Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the OKYO Pharma dividend yield?

OKYO Pharma does not currently pay a dividend.

Does OKYO Pharma pay a dividend?

OKYO Pharma does not currently pay a dividend.

When does OKYO Pharma next pay dividends?

OKYO Pharma does not currently pay a dividend.

How do I buy OKYO Pharma shares?

To buy shares in OKYO Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of OKYO Pharma?

Shares in OKYO Pharma are currently trading at 18p, giving the company a market capitalisation of £100.9m.

Where are OKYO Pharma shares listed? Where are OKYO Pharma shares listed?

Here are the trading details for OKYO Pharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: OKYO
What kind of share is OKYO Pharma?

Based on an overall assessment of its quality, value and momentum, OKYO Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a OKYO Pharma share price forecast 2020?

We were not able to load any forecast data for OKYO Pharma.

How can I tell whether the OKYO Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OKYO Pharma. Over the past six months, the relative strength of its shares against the market has been 1.17k%. At the current price of 18p, shares in OKYO Pharma are trading at 0.411k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the OKYO Pharma PE Ratio?

We were not able to find PE ratio data for OKYO Pharma.

Who are the key directors of OKYO Pharma?

We were unable to find the directors for OKYO Pharma.

Who are the major shareholders of OKYO Pharma?

Here are the top five shareholders of OKYO Pharma based on the size of their shareholding:

Similar to OKYO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.